Robert Douglas Knight - 05 Apr 2022 Form 4 Insider Report for NexImmune, Inc.

Role
Chief Medical Officer
Signature
/s/ Ilse Johnson, Attorney-in-fact
Issuer symbol
NEXI on OTC
Transactions as of
05 Apr 2022
Net transactions value
$0
Form type
4
Filing time
07 Apr 2022, 19:13:05 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEXI Stock Options (Right to Buy) Award $0 +48,000 $0.000000 48,000 05 Apr 2022 Common Stock 48,000 $4.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Knight's continued service to the corporation on each vesting date.